Celldex Therapeutics, Inc. (Celldex), formerly AVANT Immunotherapeutics, Inc., is a biopharmaceutical company engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The Company’s product pipeline consists of therapeutic cancer vaccines, monoclonal antibodies, single-dose, oral vaccines aimed at protecting travelers and people in regions where infectious diseases are endemic and a treatment to reduce complement-mediated tissue damage. During the year ended December 31, 2008, the Company had one product on the market and six products in clinical development. On March 7, 2008, Celldex merged with Callisto Merger Corporation. In January 2009, the Company sold the poultry vaccines business, consisting of MeganVac 1 and MeganEgg, to LAHI. In October 2009, Celldex Therapeutics, Inc. announced the completion of its acquisition of CuraGen Corporation.